Progress in development of disease-modifying treatments in Parkinson's Disease

Progress in development of disease-modifying treatments in Parkinson's Disease Henri Huttunen, Chief Scientific Officer, Herantis Pharma Plc, charts progress in the development of disease-modifying treatments for Parkinson’s disease. Recent FDA approvals of two potentially disease-modifying Alzheimer’s disease drugs give hope that similar successes in Parkinson’s disease may be around the corner. However, despite the recent advances in understanding complex disease biology and the development of novel drug targets and biomarkers, progress in the clinical development of new treatments remains slow.